Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 4

3(33.3%)

Phase 1

1(11.1%)

Phase 2

1(11.1%)

9Total

N/A(4)

Phase 4(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07445074Not ApplicableRecruiting

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Role: collaborator

NCT05992402Not ApplicableRecruiting

Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery

Role: collaborator

NCT03338478Not ApplicableCompleted

Balance and Anti-Epileptic Drugs

Role: collaborator

NCT02084303Not ApplicableCompleted

Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI

Role: collaborator

NCT01733394Phase 4Completed

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

Role: collaborator

NCT00524134Phase 2Terminated

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

Role: collaborator

NCT02268578Phase 1Withdrawn

Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy

Role: collaborator

NCT01713777Phase 4Completed

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design

Role: collaborator

NCT00835627Phase 4Completed

Treatment Trial for Psychogenic Nonepileptic Seizures

Role: collaborator

All 9 trials loaded